We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+22.05%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$2.93M
Cap. Flow
-$20M
Cap. Flow %
-16.59%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
DTIL icon
Precision BioSciences
DTIL
+$8.88M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$7.16M
3
YARW
Yarrow Bioscience
YARW
+$3.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
1
DELISTED
Akero Therapeutics
AKRO
$78.5M 65.27%
3,150,019
– –
DTIL icon
2
Precision BioSciences
DTIL
$215M
$23.3M 19.33%
93,053
-40,544
-30% -$8.88M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$16.4M 13.62%
501,584
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$2.14M 1.78%
456,770
– –
YARW
5
Yarrow Bioscience
YARW
$98.8M
– –
-406
Closed -$3.92M
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-160,333
Closed -$7.16M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2020 Portfolio in Review

As of Q2 2020, venBio Partners held 6 positions worth $120M, up 2.5% from $117M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $20M in Q2 2020, closing 2 positions and reducing 1 holding. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $7.16M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q2 2020 reduction was Precision BioSciences, cutting an estimated $8.88M.
  • venBio Partners fully exited Turning Point Therapeutics, Inc. Common Stock in Q2 2020, selling an estimated $7.16M.
  • venBio Partners's ten largest holdings make up 100% of its $120M portfolio in Q2 2020.
  • venBio Partners opened 0 new positions and closed 2 in Q2 2020.
  • venBio Partners's portfolio value rose 2.5% quarter-over-quarter to $120M.

Based on venBio Partners's 13F filing for Q2 2020, filed 14 Aug 2020.